In psoriasis subjects, we identified IL-17A and KLK-7 as robust biomarkers to PASI total severity scores, which were significantly downregulated by apremilast, making the two biomarkers uniquely positioned to link disease- and apremilast- centric biology. This evidence concerns the gene IL17A and psoriasis.